The AIM with Immunotherapy Initiative – Home › Forums › Immunotherapy › Expectations for therapy › Adjuvant pembrolizumab › Reply To: Adjuvant pembrolizumab
February 19, 2018 at 10:50 pm #4704
Expert NurseSuzanne McGettigan
Great comments Virginia and Kathy..
It is such an amazing time for melanoma therapies and cancer therapies in general. As many of these therapies receive approvals in multiple cancer types, it is essential to review the PI for specifics around the approvals as well as for nuances in toxicity profiles from one tumor type to another. For many of our colleagues who don’t specialize in a single tumor type, this is even more important.